Silver Book Fact

Dramatic increase of antibiotic resistance between 1981 and 2001

Fact image

Increase in antibiotic resistance over 20 year period

National Nosocomial Infections Surveillance (NNIS) System. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990 – May 1999, Issued June 1999. Am J Infect Control. 1999; 27(6): 520-32. http://www.ajicjournal.org/article/S0196-6553%2899%2970031-3/fulltext

Reference

Title
National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990 – May 1999, Issued June 1999
Publication
Am J Infect Control
Publication Date
1999
Authors
National Nosocomial Infections Surveillance (NNIS) System
Volume & Issue
Volume 27, Issue 6
Pages
520-32
URL
Read Full Resource

Categories

  • Cost of Disease
  • Prevalence & Incidence

Related Facts

  • ~1 in 20 hospitalized patients will get an HAI
    Around 1 in 20 hospitalized patients will contract a healthcare-associated infection, the most common complication of hospital care.  
  • Late Mortality and Sepsis
    Compared with patients not in the hospital, sepsis in hospitalized patients was associated with a 22.1%  increase in late mortality during a 2 year follow-up period.  
  • Sepsis hospitalization rate increases with age
    The rate of hospitalization for sepsis/septicemia in 2008 was around 30 times higher for patients ages 85 and older, than for those under the age of 65.  
  • Most common principal diagnoses for hospitalized patients with HAIs
    The most common principal diagnoses for hospitalized patients with HAIs are: Septicemia 11.8% Adult respiratory failure 5.9% Complications from surgical or medical care 4.1%  
  • 10 most common pathogens leading to HAIs
    The 10 most common pathogens leading to HAIs: Coagulase-negative staphylococci 15% Staphylococcus aureus 15% Enterococcus species 12% Candida species 11% Escherichia coli 10% Pseudomonas aeruginosa 8% Klebsiella pneumoniae 6% Enterobacter species 5% Acinetobacter baumannii 3% Klebsiella oxytoca 2%